Market capitalization | $746.94m |
Enterprise Value | $466.67m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 7.31 |
P/S ratio (TTM) P/S ratio | 11.69 |
P/B ratio (TTM) P/B ratio | 1.55 |
Sales growth (TTM) Sales growth | 22.14% |
Turnover (TTM) Turnover | $63.88m |
As a free StocksGuide basic user, you can view the scores for all 6,954 shares worldwide.
8 Analysts have issued a CureVac N.V. forecast:
8 Analysts have issued a CureVac N.V. forecast:
Mar '24 |
+/-
%
|
||
Turnover | 13 13 |
76%
76%
|
|
Gross income | -36 -36 |
44%
44%
|
|
EBITDA | -78 -78 |
-
|
EBIT (operating result) EBIT | -84 -84 |
29%
29%
|
Net profit | -77 -77 |
-
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
CureVac BV is a clinical-stage biopharmaceutical Company developing tumour immunotherapy. It offers RNA optimization that encode functional proteins that replace defective or missing proteins using the cell's intrinsic translation machinery. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.
Head office | Netherlands |
CEO | Alexander Zehnder |
Employees | 1,172 |
Founded | 2020 |
Website | www.curevac.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.